Georgia's Online Cancer Information Center

Encouraging Early Results for Use of Immunotherapy in Triple-Neg Breast Cancer

7/14/2017, Meghan Mooradian, MD, MedPage Today

"Accumulating evidence suggests that immune checkpoint inhibitors may be effective in the treatment of breast cancer, particularly triple-negative breast cancer (TNBC). Research has demonstrated that about 20% of TNBC specimens express PD-L1, which has been shown to be a reliable predictive biomarker of immune checkpoint efficacy. In addition to tumor PD-L1 expression, tumor-infiltrating lymphocytes (TILs) have been shown to correlate with response to checkpoint blockade. Recent studies suggest that about 90% of TNBC tumors have at least one stromal TIL, with 20% on average. While the updated response rate from the KEYNOTE-012 study was not particularly impressive (18.5%), the duration of response from pembrolizumab in patients with PD-L1-positive TNBC was noteworthy in a subset of patients. Further research will need to better assess the characteristics of patients who responded to checkpoint inhibition in this study. Moreover, novel studies testing new strategies to augment the T-cell response prior to checkpoint blockade (i.e., with chemotherapy or peptide vaccines) will elucidate alternative approaches to ensure the most robust response to this new breakthrough therapy."

This article was a collaboration between MedPage Today and ASCO.  Meghan Mooradian, MD, Clinical and Reserach Fellow at the Massachusetts General Hospital is the author.

 

To read the full article on MedPage Today, click here.

Media, News & Events

Greetings of gratitude from our president and CEO

Lynn gives a message of thanks and a glimpse into what's to come in 2022.

11/18/2021

Cancer Center opens in Braselton

“This new collaborative space puts our patients’ needs front and center by providing a more cohesive environment with access to both medical oncology/hematology and radiation oncology services within steps of each other,” says Charles Nash III, MD, FACP, medical director of NGMC’s Cancer Services and medical oncologist with Longstreet Clinic (and Georgia CORE Board member).

6/29/2021

Subscribe to Our Newsletter

Our email newsletter allows you to get the most up-to-date information right in your Inbox.

Subscribe Now
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.